Jan Beger’s Post

View profile for Jan Beger, graphic

Global Head of AI Advocacy @ GE HealthCare

This study provides an extensive examination of #Cancer statistics in the United States, including projected new cases and deaths for 2022. It analyzes data from various national registries and highlights trends in incidence and mortality rates for different types of cancer. In 2022, it is projected that there will be 1,918,030 new cancer cases and 609,360 cancer deaths in the US, with lung cancer causing approximately 350 deaths per day. 1️⃣ The incidence of female breast cancer has been rising slowly, at a rate of 0.5% annually from 2014 to 2018. 2️⃣ Prostate cancer incidence remained stable during the same period, but there was a significant increase (4% to 6% annually) in cases of advanced disease, leading to a rise in the proportion of prostate cancer diagnosed at a distant stage, from 3.9% to 8.2% in a decade. 3️⃣ Lung cancer, the leading cause of cancer death, showed a steep decline in incidence for advanced disease, while rates for localized-stage lung cancer increased suddenly by 4.5% annually. This shift contributed to an increase in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and improved 3-year relative survival rates (from 21% to 31%). 4️⃣ Mortality patterns generally mirrored incidence trends, with accelerated declines for lung cancer, slower declines for breast cancer, and stable rates for prostate cancer. Reading this paper offers insights into the current state and trends of cancer occurrence and mortality in the United States. It underscores the importance of early detection, cancer screening, and targeted interventions in managing cancer and reducing mortality rates. The paper's detailed analysis can inform healthcare professionals, policy makers, and researchers aiming to devise strategies for cancer control. ✍🏾 Siegel, RL,  Miller, KD,  Fuchs, HE,  Jemal, A.  Cancer statistics, 2022. CA Cancer J Clin. 2022. DOI: 10.3322/caac.21708

  • No alternative text description for this image
SMJ Mortazavi

Professor of Medical Physics, Shiraz University of Medical Sciences (SUMS)

1y

The missing issue of screen time As mentioned in this paper, according to the American Cancer Society, the incidence of female breast cancer in the United States increased slightly by 0.5% annually from 2014 through 2018. While several factors, such as changes in lifestyle and reproductive patterns, as well as improvements in screening and detection methods, may contribute to the increase, breast cancer is a complex disease with many risk factors, including age, genetics, lifestyle factors, and environmental exposures. The issue of screen time, particularly before bedtime, has been a topic of concern in relation to breast cancer risk. Some studies have suggested a potential link between exposure to artificial light at night and breast cancer risk, though the evidence is still limited. Additionally, there is some evidence to suggest that increased digital screen time, particularly before bedtime, may be linked to an increased risk of breast cancer. While the impact of increased digital screen time on breast cancer incidence is likely to be small, however, in women with mutations in the BRCA1 and BRCA2 genes, increased digital screen time before bedtime may be a more significant risk factor for breast cancer.

Ludmila Jagiellicz

Strategy Facilitator and Advisor at Compelling Strategies

1y

Not surprisingly I can think of a number of people I know who have had one of these cancers, or have gone through still-consequential but non-cancerous conditions. They all bravely faced this challenge. Not all survived. Healthcare is a serious business. As are prevention and detection. Unfortunately these businesses are still often thought of as bottom-line focused, rather than as outcome-based though no less efficient. And the business of health can even become quite politicized and divisive. While we advance in areas such as AI-assisted research into treatments and cures, we continue to lag in supporting and investing in caregivers, both today and into the future. All I can do is laud the folks who are working on solutions. May their counter-offensives succeed.

Prof. Dr. med. Thomas Henzler

Professor of Radiology; Experienced C-Level healthcare manager & healthtech entrepreneur

1y

#3:Let’s further push lung cancer screening in order to see even less advanced disease of LC in the near future. Early diagnosis of localized disease is most effective for survival and more cost-efficient when compared to later diagnosis of advanced disease.

Yael Maizels, PhD

Science Communicator and Data Consultant

1y

What a fascinating post- thank you for sharing. So interesting that while breast cancer has higher incidence in women lung cancer has higher mortality. It's known also that the faction of non-smoking women with lung cancer is rising at worrying rates. Also fascinating that overall women have less predicted incidence and mortality although cancer risk is known to increase with age and women live longer than men.

Like
Reply
Nitish Sharma

Cloud Solutions Architect || Ex Kyndryl | IBM | Deloitte | IQVIA | ARIS Global | Bioclinica | MCA - JLPT N2

1y

These statistics are sobering and underline the critical need for continued research and advancement in cancer treatments.

James Timmins

Sr Business Developer, Quantoom Biosciences

1y

In lung cancer is it screening or the welcome use of checkpoint inhibitors? What is the best qualifying test? TMB (tumor mutational burden)? The combination with mRNA extraction from tumors as a booster vaccine awaits...

Like
Reply
Prof. Dr. med. Thomas Henzler

Professor of Radiology; Experienced C-Level healthcare manager & healthtech entrepreneur

1y

#2: Thats a disappointing development. It will be interesting to analyse differences between countries with large usage of multiparametric MRI and those with less usage or restrictions in mpMRI reimbursement.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics